SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.230
-0.120 (-8.87%)
At close: Apr 1, 2025, 4:00 PM
1.279
+0.049 (3.99%)
After-hours: Apr 1, 2025, 7:58 PM EDT
SAB Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Cash & Equivalents | 8.9 | 56.57 | 15.05 | 33.21 | 12.61 | Upgrade
|
Short-Term Investments | 11.86 | - | - | - | - | Upgrade
|
Cash & Short-Term Investments | 20.76 | 56.57 | 15.05 | 33.21 | 12.61 | Upgrade
|
Cash Growth | -63.30% | 275.93% | -54.69% | 163.33% | 98.72% | Upgrade
|
Accounts Receivable | - | - | 5.56 | 8.01 | 20.57 | Upgrade
|
Other Receivables | 0.05 | - | - | - | - | Upgrade
|
Receivables | 0.05 | - | 5.56 | 8.01 | 20.57 | Upgrade
|
Prepaid Expenses | 2.98 | 2.34 | 1.49 | 2.64 | 1.28 | Upgrade
|
Restricted Cash | - | - | - | 6.34 | - | Upgrade
|
Total Current Assets | 23.79 | 58.91 | 22.1 | 50.19 | 34.46 | Upgrade
|
Property, Plant & Equipment | 19.92 | 24.68 | 28.34 | 30.95 | 22.08 | Upgrade
|
Long-Term Deferred Charges | 0.26 | - | - | - | - | Upgrade
|
Other Long-Term Assets | 0.22 | 0.35 | 0.47 | - | - | Upgrade
|
Total Assets | 44.2 | 83.94 | 50.9 | 81.14 | 56.54 | Upgrade
|
Accounts Payable | 1.69 | 0.95 | 3.68 | 4.46 | 7.38 | Upgrade
|
Accrued Expenses | 5.47 | 6.69 | 9.83 | 11.91 | 1.28 | Upgrade
|
Current Portion of Long-Term Debt | 0.28 | 1.05 | 0.77 | 1.8 | 0.54 | Upgrade
|
Current Portion of Leases | 0.54 | 0.8 | 0.62 | 1.3 | 1.12 | Upgrade
|
Current Unearned Revenue | - | 1.32 | - | 0.1 | 0.1 | Upgrade
|
Other Current Liabilities | - | - | 0.09 | 6.89 | 0.64 | Upgrade
|
Total Current Liabilities | 7.98 | 10.81 | 14.99 | 26.46 | 11.06 | Upgrade
|
Long-Term Debt | - | - | 0.54 | - | 0.17 | Upgrade
|
Long-Term Leases | 3.86 | 4.05 | 3.99 | 5.42 | 6.3 | Upgrade
|
Other Long-Term Liabilities | 6.39 | 11.77 | 0.32 | 10.72 | - | Upgrade
|
Total Liabilities | 18.23 | 26.64 | 19.85 | 42.59 | 17.53 | Upgrade
|
Common Stock | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Additional Paid-In Capital | 155.79 | 152.86 | 84.45 | 67.67 | 50.99 | Upgrade
|
Retained Earnings | -124.17 | -90.06 | -47.87 | -29.13 | -11.98 | Upgrade
|
Treasury Stock | -5.52 | -5.52 | -5.52 | - | - | Upgrade
|
Comprehensive Income & Other | -0.14 | 0.03 | - | - | - | Upgrade
|
Total Common Equity | 25.97 | 57.3 | 31.06 | 38.55 | 39.01 | Upgrade
|
Shareholders' Equity | 25.97 | 57.3 | 31.06 | 38.55 | 39.01 | Upgrade
|
Total Liabilities & Equity | 44.2 | 83.94 | 50.9 | 81.14 | 56.54 | Upgrade
|
Total Debt | 4.67 | 5.91 | 5.93 | 8.52 | 8.13 | Upgrade
|
Net Cash (Debt) | 16.09 | 50.66 | 9.12 | 24.69 | 4.48 | Upgrade
|
Net Cash Growth | -68.23% | 455.59% | -63.07% | 450.61% | - | Upgrade
|
Net Cash Per Share | 1.74 | 9.17 | 2.09 | 9.03 | 1.66 | Upgrade
|
Filing Date Shares Outstanding | 9.29 | 9.23 | 5.04 | 4.3 | 3.52 | Upgrade
|
Total Common Shares Outstanding | 9.29 | 9.23 | 5.04 | 4.35 | 3.52 | Upgrade
|
Working Capital | 15.81 | 48.09 | 7.1 | 23.74 | 23.39 | Upgrade
|
Book Value Per Share | 2.80 | 6.21 | 6.16 | 8.86 | 11.08 | Upgrade
|
Tangible Book Value | 25.97 | 57.3 | 31.06 | 38.55 | 39.01 | Upgrade
|
Tangible Book Value Per Share | 2.80 | 6.21 | 6.16 | 8.86 | 11.08 | Upgrade
|
Machinery | - | 11.99 | 11.57 | 8.87 | 6.33 | Upgrade
|
Construction In Progress | - | - | 0.31 | 4.61 | 6.73 | Upgrade
|
Leasehold Improvements | - | 9.3 | 9.3 | 5.7 | 0.19 | Upgrade
|
Updated Nov 6, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.